An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver

Chávez Tapia, Norberto C. y Ridruejo, Ezequiel y De Mattos, Angelo Alves y Bessone, Fernando y Daruich, Jorge y Sánchez Ávila, Juan F. y Cheinquer, Hugo y Zapata, Rodrigo y Uribe Esquivel, Misael y Bosques Padilla, Francisco Javier y Gadano, Adrián y Soza, Alejandro y Dávalos Moscol, Milagros y Marroni, Claudio y Muñoz Espinoza, Linda y Castro Narro, Graciela y Paraná, Raymundo y Méndez Sánchez, Nahum (2013) An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of hepatology, 12 (2). S3-S35. ISSN 1665-2681

Vista previa

Texto 23451.pdf - Versión Publicada Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (583kB) | Vista previa

Resumen

Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.

Actions (login required)

Ver elemento